technology

press releases

Date Title and Summary Additional Formats
Toggle Summary BOTHELL, Wash., July 11, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary -- Pivotal PROMISE 1 top-line results show eptinezumab met primary and key secondary endpoints -- -- Beginning day 1 after first dose significant reduction in proportion of patients experiencing migraine -- -- Average of 1 in 5 patients had no migraines in any given month over months 1 through 6 -- View HTML
Toggle Summary BOTHELL, Wash., June 07, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), today announced four data presentations at the 59 th Annual Scientific Meeting of the American Headache Society in Boston from June 8-11, 2017. The presentations will highlight Phase 2b clinical data and View HTML
Toggle Summary BOTHELL, Wash., May 10, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Bank of America Merrill Lynch 2017 Health Care View HTML
Toggle Summary - Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24 to 48 hours after a single infusion - BOTHELL, Wash., April 28, 2017 (GLOBE NEWSWIRE) --  Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company View HTML
Toggle Summary Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017 Conference call set for 5 p.m. EDT today BOTHELL, Wash., April 27, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company View HTML
Toggle Summary - Eptinezumab rational design results in differentiated clinical profile for migraine prevention therapy - - Eptinezumab responders showed significant and sustained reduction in migraine days following a single infusion -   BOTHELL, Wash., April 24, 2017 (GLOBE NEWSWIRE) -- Alder View HTML
Toggle Summary BOTHELL, Wash., April 20, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals®, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2017 financial and operating results after the View HTML
Toggle Summary Former Merck Chief Marketing Officer, Experienced Director of Biopharma Companies Joins Alder Board as Company Moves Closer to First BLA Submission and Planned Commercialization View HTML
Toggle Summary BOTHELL, Wash., March 28, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16 th Annual Needham Healthcare Conference View HTML